PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care, today announced a $33 million Series B on the heels of the adoption of its Generative AI platform (GENEVA OS™) by healthcare institutions, data platforms, research institutions, life sciences companies and more.

加利福尼亚州帕洛阿尔托（商业新闻短讯）--Atropos Health是将现实世界的临床数据转化为高质量个性化现实世界护理证据的先驱，继医疗机构、数据平台、研究机构、生命科学公司等采用其生成性AI平台（GENEVA OS™）之后，今天宣布推出3300万美元的B系列产品。

The funding was led by Valtruis, with participation from new strategic investors including Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, along with existing investors Breyer Capital, Emerson Collective, and Presidio Ventures..

资金由Valtruis牵头，新的战略投资者（包括Cencora Ventures、McKesson Ventures和Merck Global Health Innovation Fund）以及现有投资者Breyer Capital、Emerson Collective和Presido Ventures参与。。

Atropos Health was founded in 2019 by Brigham Hyde Ph.D., Nigam Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., originally developed as the “Green Button” project at Stanford University. The trio are leaders in applications of AI and real-world evidence research in healthcare, and on a mission to democratize access to high-quality real-world evidence (RWE) as a means to improve decision making and outcomes in healthcare.

Atropos Health于2019年由Brigham Hyde博士、Nigam Shah MBBS博士和Saurabh Gombar博士创立，最初是斯坦福大学的“绿色按钮”项目。这三人是人工智能和现实世界证据研究在医疗保健中应用的领导者，他们的使命是使获得高质量现实世界证据（RWE）的民主化，以此作为改善医疗保健决策和结果的手段。

Since then, the company has emerged as a leader in the application of generative AI thanks to unique vertical user experiences like ChatRWD™ which reduces the time to produce high-quality publication-grade real-world evidence from months to minutes through a chat-based AI co-pilot..

从那时起，该公司凭借独特的垂直用户体验（如ChatRWD™等）成为了生成性人工智能应用领域的领导者，通过基于聊天的人工智能联合试点，将生成高质量出版物级真实世界证据的时间从数月缩短到数分钟。。

“As excitement over the application of Generative AI technology in healthcare turns from potential to practical applications, the focus of providers, life sciences, and other healthcare stakeholders turns to quality, transparency, and automation backed by tangible ROI. For decades, high-quality clinical evidence has served as the currency of value in healthcare.

“随着对生成性人工智能技术在医疗保健中的应用的兴奋从潜在应用转向实际应用，提供者，生命科学和其他医疗保健利益相关者的重点转向由有形投资回报率支持的质量，透明度和自动化。几十年来，高质量的临床证据一直是医疗保健的价值货币。

Atropos Health is built on investment in scaling the production of high-quality, transparent, and now real-time evidence production that matches the standards of the clinical and research communities,” said Brigham Hyde, CEO and Co-Founder of Atropos Health. “This funding round, which includes multiple major strategic stakeholders in the healthcare ecosystem, is validation that our platform is rapidly becoming the standard not only for automation and user experience, but also as the trusted quality layer between healthcare data and the critical evidence needed to better inform patient care, research, and policy.”.

Atropos Health的基础是投资于扩大高质量，透明，现在实时的证据生产，符合临床和研究社区的标准，”Atropos Health首席执行官兼联合创始人Brigham Hyde说。“这轮融资包括医疗保健生态系统中的多个主要战略利益相关者，它验证了我们的平台不仅正在迅速成为自动化和用户体验的标准，而且正在成为医疗保健数据与更好地告知患者护理，研究和政策所需的关键证据之间值得信赖的质量层。”。

Investing in Real-World Evidence for Value-Based Care Decision-Making

投资于基于价值的护理决策的现实世界证据

With this funding, Atropos Health plans to further its stake in value-based care. The company’s portfolio of evidence-generating applications supports whole-person care and value-based performance and has long been utilized by Atropos Health partners including Arcadia. Through Atropos Health, healthcare organizations are able to accelerate appropriate clinical decision-making to drive high-value, low-cost care for patients based on their unique physiology.

有了这笔资金，Atropos Health计划进一步发展其在基于价值的护理中的股份。该公司的证据生成应用程序组合支持全人护理和基于价值的绩效，长期以来一直被包括阿卡迪亚在内的Atropos Health partners使用。通过Atropos Health，医疗保健组织能够加速适当的临床决策，根据患者独特的生理机能为患者提供高价值，低成本的护理。

To drive this mission further, Atropos Health is welcoming value-based care veteran Mike Spadafore to its board..

为了进一步推动这项使命，Atropos Health欢迎价值护理老兵Mike Spadafore加入其董事会。。

“For nearly 15 years, I’ve had a front-row seat to value-based care's evolution and positive impact on patients, physicians, and communities. I am excited about Atropos Health and its ability to automate personalized, real-world evidence at scale for both providers and researchers,” said Spadafore, Managing Director of Valtruis.

Valtruis董事总经理Spadafore表示：“近15年来，我一直在重视基于价值的护理的发展以及对患者、医生和社区的积极影响。我对Atropos Health及其为提供者和研究人员大规模自动化个性化现实世界证据的能力感到兴奋。”。

“Atropos Health has the potential to dramatically improve existing workflows across both life sciences and health systems, in turn improving clinician decision-making and driving better outcomes for patients. We are thrilled to partner with Atropos in this journey.”.

“Atropos Health有可能极大地改善生命科学和卫生系统的现有工作流程，进而改善临床医生的决策并为患者带来更好的结果。我们很高兴在此旅程中与Atropos合作。”。

Expanding the Atropos Evidence™ Network Including Vertical Integrations with Oncology and Specialty areas

扩展Atropos Evidence™网络，包括与肿瘤学和专业领域的垂直整合

As a part of this round, Atropos Health will enter into strategic relationships with partners from life sciences and vertically integrated healthcare players. Through Cencora, a leading global pharmaceutical solutions organization, Atropos Health will bring its real-world evidence platform to oncology and specialty care.

作为本轮谈判的一部分，Atropos Health将与生命科学和垂直整合医疗保健参与者的合作伙伴建立战略关系。通过全球领先的药物解决方案组织Cencora，Atropos Health将为肿瘤学和专科护理提供真实世界的证据平台。

Evidence for care is critical in the rapidly evolving treatment landscape for oncology, where the stakes are high for cancer patients. Now, oncologists and researchers can leverage the Atropos Evidence Network of millions of anonymized patient data converted to high-quality evidence to inform their decision-making process.

在快速发展的肿瘤学治疗领域，护理证据至关重要，癌症患者的风险很高。现在，肿瘤学家和研究人员可以利用Atropos证据网络，将数百万匿名患者数据转换为高质量证据，为他们的决策过程提供信息。

In turn, pharmaceutical customers of Atropos Health, such as Janssen Research & Development, LLC (Janssen), a Johnson & Johnson company, can leverage this evidence network to drive critical R&D initiatives and accelerate the time of the development of the next treatment..

反过来，Atropos Health的制药客户，如强生公司Janssen Research&Development，LLC（Janssen），可以利用这一证据网络来推动关键的研发计划，并加快下一种治疗方法的开发时间。。

“Atropos Health addresses a very real problem that both health systems and pharmaceutical manufacturers face in turning medical data into insights in a timely, predictable, and cost-effective manner.” said Michelle Snyder, Partner at McKesson Ventures. “As leading industry players increasingly recognize the value of having the right data, rather than just having the most data, Atropos Health stands out in its ability to understand and score datasets in a compliant and secure manner in order to accelerate research and improve patient outcomes.”.

McKesson Ventures合伙人米歇尔·斯奈德（MichelleSnyder）说：“Atropos Health解决了卫生系统和制药制造商在及时、可预测和经济高效地将医疗数据转化为见解方面面临的一个非常现实的问题。”。“随着领先的行业参与者越来越认识到拥有正确数据的价值，而不仅仅是拥有最多的数据，Atropos Health凭借其以合规和安全的方式理解和评分数据集的能力而脱颖而出，以加速研究并改善患者结果。”。

Expanding Investment in Atropos Health Generative Application ChatRWD

扩大对Atropos健康生成应用程序ChatRWD的投资

Launched in Beta in Q4 of 2023, ChatRWD cuts production of high quality real-world evidence down from months to minutes through clinical and research friendly chat based user experience. While the speed of ChatRWD is already revolutionary, accuracy and transparency of results is a core tenant of Atropos Health foundation.

ChatRWD于2023年第四季度推出测试版，通过临床和研究友好的基于聊天的用户体验，将高质量真实世界证据的制作时间从几个月减少到几分钟。虽然ChatRWD的速度已经是革命性的，但结果的准确性和透明度是Atropos Health foundation的核心租户。

Built on the core technology GENEVA OS, ChatRWD is a LLM independent framework (enabling institutions to maintain LLM security and integrity) that is built to eliminate hallucination risk that is unacceptable in the clinical evidence arena. A pending publication will further outline this approach and the benefits to accuracy in the generation of evidence.

ChatRWD建立在核心技术GENEVA OS的基础上，是一个独立于LLM的框架（使机构能够维护LLM的安全性和完整性），旨在消除临床证据领域不可接受的幻觉风险。即将出版的出版物将进一步概述这种方法以及在产生证据方面对准确性的好处。

Investment in this round will support the full launch of ChatRWD with the potential to democratize high-quality, accurate, transparent, and personalized real-world evidence for everyone..

这一轮的投资将支持ChatRWD的全面推出，有可能为每个人提供高质量、准确、透明和个性化的现实世界证据。。

About Atropos Health

关于Atropos Health

Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more.

Atropos Health是GENEVA OS™的开发人员，GENEVA OS™是一种操作系统，用于跨强大的现实数据网络快速提供医疗保健证据。医疗保健和生命科学组织与Atropos Health合作，缩小从实验室到床边的证据差距，通过数据驱动的护理改善个体患者的结果，加速推进医学领域的研究等等。

We aim to transform healthcare with timely, relevant real-world evidence..

我们的目标是通过及时、相关的现实证据来改变医疗保健。。

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.

要了解有关Atropos Health的更多信息，请访问www.atroposhealth.com或通过LinkedIn或follow on X（Twitter）@atroposhealth进行连接。